CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade AstraZeneca PLC - GBP - AZNl CFD

116.90
0.17%
Market Trading Hours* (UTC) Opens on Tuesday at 07:00

Mon - Fri: 07:00 - 11:00 11:03 - 15:30

  • Summary
  • Historical Data
Trading сonditions
Spread 2.48
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02461 %
Charges from full value of position ($-4.68)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02461%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002692 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002692%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.65
Currency GBP
Margin 5.00%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

Key Stats
Prev. Close 117.1
Open 117.86
1-Year Change 7.53%
Day's Range 116.9 - 119.14
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 11, 2024 117.10 -0.34 -0.29% 117.44 117.96 116.44
Oct 10, 2024 117.46 0.18 0.15% 117.28 118.32 117.14
Oct 9, 2024 116.46 -0.62 -0.53% 117.08 117.82 116.46
Oct 8, 2024 116.72 0.06 0.05% 116.66 117.44 116.62
Oct 7, 2024 117.86 0.38 0.32% 117.48 118.32 116.46
Oct 4, 2024 117.34 -0.68 -0.58% 118.02 119.08 115.76
Oct 3, 2024 119.46 -0.73 -0.61% 120.19 120.69 119.06
Oct 2, 2024 119.46 1.58 1.34% 117.88 119.95 117.74
Oct 1, 2024 117.56 1.12 0.96% 116.44 117.72 115.54
Sep 30, 2024 115.58 -0.48 -0.41% 116.06 117.12 115.52
Sep 27, 2024 115.20 0.28 0.24% 114.92 117.18 114.92
Sep 26, 2024 116.72 -0.58 -0.49% 117.30 117.42 114.30
Sep 25, 2024 115.42 1.08 0.94% 114.34 115.70 112.82
Sep 24, 2024 112.82 -2.18 -1.90% 115.00 116.08 112.80
Sep 23, 2024 115.40 0.40 0.35% 115.00 117.24 115.00
Sep 20, 2024 115.56 -2.54 -2.15% 118.10 119.30 115.56
Sep 19, 2024 118.76 -0.42 -0.35% 119.18 120.25 118.52
Sep 18, 2024 118.60 -0.56 -0.47% 119.16 119.26 118.14
Sep 17, 2024 119.70 0.37 0.31% 119.33 120.95 119.02
Sep 16, 2024 118.50 -0.90 -0.75% 119.40 120.45 118.50

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AstraZeneca - GBP Company profile

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

Industry: Pharmaceuticals (NEC)

1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB

News

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

US Core CPI tipped to remain unchanged in September

US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.

07:10, 9 October 2024

RBNZ expected to deliver “jumbo” rate cut

The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.

08:48, 8 October 2024

September Non-Farm Payrolls eases fears of US economic slowdown

Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.

07:44, 8 October 2024

Gold's recent story

Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.

15:36, 7 October 2024

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

People also watch

XRP/USD

0.56 Price
+4.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Oil - Crude

71.17 Price
-5.140% 1D Chg, %
Long position overnight fee 0.0172%
Short position overnight fee -0.0392%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

20,454.80 Price
+1.090% 1D Chg, %
Long position overnight fee -0.0248%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,649.75 Price
-0.280% 1D Chg, %
Long position overnight fee -0.0177%
Short position overnight fee 0.0094%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading